John Radford

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

Medicine, Hematology, Pharmacology +17

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2017 · 985 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

B. Coiffier, Corinne Haïoun, Nicolas Ketterer et al. · PubMed · 1998 · 898 citations

Life Sciences, Immunology, Oncology +15

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

Peter Johnson, Massimo Federico, Amy A. Kirkwood et al. · New England Journal of Medicine · 2016 · 798 citations · Full text

Medicine, Nuclear Medicine, Oncology +15

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus et al. · New England Journal of Medicine · 2017 · 764 citations · Full text

Medicine, Oncology, Pharmacotherapy +15